Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

Traci E. Yamashita, John P. Phair, Alvaro Muñoz, Joseph B. Margolick, Roger Detels, Stephen J. O'Brien, John W. Mellors, Steven M. Wolinsky, Lisa P. Jacobson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

157 Scopus citations


Objectives: To evaluate prior antiretroviral therapy experience and host characteristics as determinants of immunologic and virologic response to highly active antiretroviral therapy (HAART). Methods: We studied 397 men from the Multicenter AIDS Cohort Study (MACS) who initiated HAART between October 1995 and March 1999. CD4 cell count and HIV-1 RNA responses to HAART were measured at the first visit following HAART (short-term) and extending from the first visit to approximately 33 months after HAART (long-term). Prior antiretroviral experience was classified into three groups based on antiretroviral therapy use during the 5 years prior to HAART. Age, race and host genetic characteristics also were assessed for their effects on treatment response. Results: Better short- and long-term CD4 cell and HIV-1 RNA responses were observed in the treatment-naive users. Intermittently and consistently experienced users did not significantly differ in response. Whereas race did not independently affect response, among those initiating HAART with > 400 × 106 CD4 cells/l, younger age and the Δ32 CCR5 genotype were associated with a better short-term CD4 cell response. There was a suggestion that having the protective CCR5 genotype also was associated with a better long-term CD4 cell response. Conclusion: Immunologic and virologic response to HAART was stronger in individuals who had no prior experience with the antiretroviral therapy agents subsequently included in their initial HAART regimen. Age, level of immune competence and immunogenetics appeared to play a role in the subsequent immune reconstitution following use of highly effective HIV therapy.

Original languageEnglish (US)
Pages (from-to)735-746
Number of pages12
Issue number6
StatePublished - Apr 13 2001


  • Genetic markers
  • HIV-1
  • Highly active antiretroviral therapy
  • Immunologic response
  • Prior antiretroviral experience
  • Virologic response

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study'. Together they form a unique fingerprint.

Cite this